Hua Ling Pharmaceuticals submitted the latest Securities Change Monthly Report to Hong Kong Exchanges and Clearing Limited on November 5, 2024, reporting the company's shareholding changes as of October 31, 2024. The report shows that Hua Ling Pharmaceuticals' statutory/registered share capital and the number of issued shares have not changed this month. The total statutory/registered share capital and total number of issued shares of common stock remain at 2,000,000,000 shares, with a face value of $0.001 per share, totaling $2,000,000. Additionally, within the company's stock options plan, the number of stock options has decreased this month, from 52,799,265 shares at the end of last month to 52,357,591 shares, mainly due to 441,674 stock options expiring. The company confirms that all securities issuance or transfer of treasury shares have been formally authorized by the board of directors and comply with all relevant listing rules and legal requirements.

Hua Ling Pharmaceuticals submitted the latest Securities Change Monthly Report to Hong Kong Exchanges and Clearing Limited on November 5, 2024, reporting the company's shareholding changes as of October 31, 2024. The report shows that Hua Ling Pharmaceuticals' statutory/registered share capital and the number of issued shares have not changed this month. The total statutory/registered share capital and total number of issued shares of common stock remain at 2,000,000,000 shares, with a face value of $0.001 per share, totaling $2,000,000. Additionally, within the company's stock options plan, the number of stock options has decreased this month, from 52,799,265 shares at the end of last month to 52,357,591 shares, mainly due to 441,674 stock options expiring. The company confirms that all securities issuance or transfer of treasury shares have been formally authorized by the board of directors and comply with all relevant listing rules and legal requirements.